Azitra, Inc. has announced positive preclinical data for its ATR-01 program, which is being developed as a potential treatment for ichthyosis vulgaris. ATR-01 utilizes an engineered strain of S. epidermidis (ATR01-616) designed to secrete functional human filaggrin protein. Preclinical results demonstrated that ATR01-616 can produce active filaggrin, deliver it through the human stratum corneum, and repair damaged model skin. Specifically, the strain reduced transepidermal water loss in ex vivo pig skin models and showed positive pharmacological activity in multiple preclinical tests. Detailed data from these studies will be presented virtually at the BIO-Europe® conference, scheduled to take place in Vienna, Austria, from November 3-5, 2025. Azitra also provided updates on its clinical programs ATR-12 and ATR-04, with further information on the ATR-01 program and its path to first-in-human studies expected in 2026.